209 related articles for article (PubMed ID: 28202739)
1. Anti-HMGCR Autoantibodies in Juvenile Idiopathic Inflammatory Myopathies Identify a Rare but Clinically Important Subset of Patients.
Tansley SL; Betteridge ZE; Simou S; Jacques TS; Pilkington C; Wood M; Warrier K; Wedderburn LR; McHugh NJ;
J Rheumatol; 2017 Apr; 44(4):488-492. PubMed ID: 28202739
[TBL] [Abstract][Full Text] [Related]
2. Clinical Characteristics of Anti-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Antibodies in Chinese Patients with Idiopathic Inflammatory Myopathies.
Ge Y; Lu X; Peng Q; Shu X; Wang G
PLoS One; 2015; 10(10):e0141616. PubMed ID: 26509687
[TBL] [Abstract][Full Text] [Related]
3. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy.
Watanabe Y; Uruha A; Suzuki S; Nakahara J; Hamanaka K; Takayama K; Suzuki N; Nishino I
J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1038-44. PubMed ID: 27147697
[TBL] [Abstract][Full Text] [Related]
4. Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study in Japan.
Watanabe Y; Suzuki S; Nishimura H; Murata KY; Kurashige T; Ikawa M; Asahi M; Konishi H; Mitsuma S; Kawabata S; Suzuki N; Nishino I
Medicine (Baltimore); 2015 Jan; 94(4):e416. PubMed ID: 25634171
[TBL] [Abstract][Full Text] [Related]
5. Anti-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibody in necrotizing myopathy: treatment outcomes, cancer risk, and role of autoantibody level.
Aggarwal R; Moghadam-Kia S; Lacomis D; Malik A; Qi Z; Koontz D; Burlingame RW; Oddis CV
Scand J Rheumatol; 2020 Sep; 49(5):405-411. PubMed ID: 31801390
[No Abstract] [Full Text] [Related]
6. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy.
Mammen AL; Chung T; Christopher-Stine L; Rosen P; Rosen A; Doering KR; Casciola-Rosen LA
Arthritis Rheum; 2011 Mar; 63(3):713-21. PubMed ID: 21360500
[TBL] [Abstract][Full Text] [Related]
7. Association of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients.
Kishi T; Rider LG; Pak K; Barillas-Arias L; Henrickson M; McCarthy PL; Shaham B; Weiss PF; Horkayne-Szakaly I; Targoff IN; Miller FW; Mammen AL;
Arthritis Care Res (Hoboken); 2017 Jul; 69(7):1088-1094. PubMed ID: 28129483
[TBL] [Abstract][Full Text] [Related]
8. Statin-naïve anti-HMGCR antibody-mediated necrotizing myopathy in China.
Jiao Y; Cai S; Lin J; Zhu W; Xi J; Li J; Yue D; Zhang T; Qiao K; Wang Y; Zhao C; Lu J
J Clin Neurosci; 2018 Nov; 57():13-19. PubMed ID: 30205933
[TBL] [Abstract][Full Text] [Related]
9. Coexistence of anti-HMGCR and anti-MDA5 identified by an unlabeled immunoprecipitation assay in a chinese patient cohort with myositis.
Huang L; Wang L; Yang Y; Chen H; Liu Y; Liu K; Liu M; Xiao Y; Zuo X; Li Y; Luo H; Zhang H; Xiao X
Medicine (Baltimore); 2018 Nov; 97(47):e13236. PubMed ID: 30461626
[TBL] [Abstract][Full Text] [Related]
10. Recurrent focal myositis developing into a generalised idiopathic inflammatory myopathy with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies.
Lim J; Ten Dam L; Baars PA; Van der Kooi AJ
BMJ Case Rep; 2019 Nov; 12(11):. PubMed ID: 31678918
[TBL] [Abstract][Full Text] [Related]
11. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy.
Tiniakou E; Pinal-Fernandez I; Lloyd TE; Albayda J; Paik J; Werner JL; Parks CA; Casciola-Rosen L; Christopher-Stine L; Mammen AL
Rheumatology (Oxford); 2017 May; 56(5):787-794. PubMed ID: 28096458
[TBL] [Abstract][Full Text] [Related]
12. Potential Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-hydroxy-3-methylglutaryl-CoA Reductase Antibodies in Immune-Mediated Necrotizing Myopathies.
Ladislau L; Arouche-Delaperche L; Allenbach Y; Benveniste O
Curr Rheumatol Rep; 2018 Aug; 20(9):56. PubMed ID: 30074107
[TBL] [Abstract][Full Text] [Related]
13. Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy.
Limaye V; Bundell C; Hollingsworth P; Rojana-Udomsart A; Mastaglia F; Blumbergs P; Lester S
Muscle Nerve; 2015 Aug; 52(2):196-203. PubMed ID: 25521389
[TBL] [Abstract][Full Text] [Related]
14. Screening for Anti-HMGCR Antibodies in a Large Single Myositis Center Reveals Infrequent Exposure to Statins and Diversiform Presentation of the Disease.
Szczesny P; Barsotti S; Nennesmo I; Danielsson O; Dastmalchi M
Front Immunol; 2022; 13():866701. PubMed ID: 35603214
[TBL] [Abstract][Full Text] [Related]
15. Spectrum of immune-mediated necrotizing myopathies and their treatments.
Pinal-Fernandez I; Mammen AL
Curr Opin Rheumatol; 2016 Nov; 28(6):619-24. PubMed ID: 27607340
[TBL] [Abstract][Full Text] [Related]
16. Anti-HMGCR antibodies in systemic sclerosis.
Hudson M; Luck Y; Stephenson M; Choi MY; Wang M; Baron M; Fritzler MJ;
Medicine (Baltimore); 2016 Nov; 95(44):e5280. PubMed ID: 27858897
[TBL] [Abstract][Full Text] [Related]
17. Proposed cut-off for reactivity of anti-HMGCR and anti-SRP antibodies in patients statin-exposed and statin-unexposed.
Carvalho AAS; Silva VGD; Vieira TF; Delgado PO; Corazini R; Feder D; Fonseca FLA
Medicine (Baltimore); 2018 Aug; 97(35):e11858. PubMed ID: 30170376
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle.
Pinal-Fernandez I; Parks C; Werner JL; Albayda J; Paik J; Danoff SK; Casciola-Rosen L; Christopher-Stine L; Mammen AL
Arthritis Care Res (Hoboken); 2017 Feb; 69(2):263-270. PubMed ID: 27111848
[TBL] [Abstract][Full Text] [Related]
19. Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies.
Rider LG; Katz JD; Jones OY
Rheum Dis Clin North Am; 2013 Nov; 39(4):877-904. PubMed ID: 24182859
[TBL] [Abstract][Full Text] [Related]
20. Analysis of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase using different technologies.
Musset L; Miyara M; Benveniste O; Charuel JL; Shikhman A; Boyer O; Fowler R; Mammen A; Phillips J; Mahler M
J Immunol Res; 2014; 2014():405956. PubMed ID: 24741598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
